UB Paderborn / Katalog / Suche / in CDI

Flexible and Stretchable Bioelectronics

Materials, 2022-02, Vol.15 (5), p.1664

2022

Volltextzugriff (PDF)

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Blood, 2018-06, Vol.131 (24), p.2661-2669

2018

Volltextzugriff (PDF)

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Journal of clinical oncology, 2013-01, Vol.31 (1), p.88-94

2013

Volltextzugriff (PDF)

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5326-5334

2008

Volltextzugriff (PDF)

Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107

Journal of clinical oncology, 2008-01, Vol.26 (2), p.183-189

2008

Volltextzugriff (PDF)

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib

Haematologica (Roma), 2022-11, Vol.107 (11), p.2630

2022

Volltextzugriff (PDF)

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

Journal of clinical oncology, 2008-07, Vol.26 (21), p.3523-3529

2008

Volltextzugriff (PDF)

Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC

Oncotarget, 2015-09, Vol.6 (28), p.26359-26372

2015

Volltextzugriff (PDF)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States

EJHaem, 2023-02, Vol.4 (1), p.135-144

2023

Volltextzugriff (PDF)

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

The lancet oncology, 2018-05, Vol.19 (5), p.649-659

2018

Volltextzugriff (PDF)

Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

Journal of clinical oncology, 1999-12, Vol.17 (12), p.3776-3785

1999

Volltextzugriff (PDF)

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2013-07, Vol.369 (1), p.32-42

2013

Volltextzugriff (PDF)

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

Blood, 2020-11, Vol.136 (Supplement 1), p.1-3

2020

Volltextzugriff (PDF)

Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e24044-e24044

2021

Volltextzugriff (PDF)

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Blood, 2017-12, Vol.130, p.1745-1745

2017

Volltextzugriff (PDF)

Abstract A135: Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A135-A135

2015

Volltextzugriff (PDF)

Rituximab: Ongoing and future clinical development

Seminars in oncology, 2002-02, Vol.29 (1), p.105-112

2002

Volltextzugriff (PDF)

Pediatric Dose Determinations for the Phase I Study of the DOT1L Inhibitor, EPZ-5676, in MLL-r Acute Leukemia: Leveraging Early Clinical Data in Adults through Physiologically-Based Pharmacokinetic Modeling

Blood, 2014-12, Vol.124 (21), p.3619-3619

2014

Volltextzugriff (PDF)

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Blood, 2015-12, Vol.126 (23), p.832-832

2015

Volltextzugriff (PDF)

Rituximab: Ongoing and future clinical development

Seminars in oncology, 2002-02, Vol.29 (1S2), p.105

2002

Volltextzugriff (PDF)

Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma

Cancer, 2003-09, Vol.98 (6), p.1196-1205

2003

Volltextzugriff (PDF)

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Blood, 2014-12, Vol.124 (21), p.387-387

2014

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Flexible and Stretchable Bioelectronics

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Abstract A135: Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors

Rituximab: Ongoing and future clinical development

Pediatric Dose Determinations for the Phase I Study of the DOT1L Inhibitor, EPZ-5676, in MLL-r Acute Leukemia: Leveraging Early Clinical Data in Adults through Physiologically-Based Pharmacokinetic Modeling

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Rituximab: Ongoing and future clinical development

Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Suchergebnisse filtern